The compounded-GLP-1 era is nearing its end. On April 30, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the remaining pathway for large-scale compounding.
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound them absent a shortage. With shortages resolved, this would remove the remaining pathway for large-scale compounding of these GLP-1s. Public comments were invited before a final decision.
The legal space for compounded GLP-1s has been shrinking for over a year, and an April proposal aimed to close it further.
The move targets the last major route for mass-scale compounding.
On April 30, 2026, the FDA announced a proposal to exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list, the list of bulk drug substances that outsourcing facilities may use to compound at scale. The agency stated it found no clinical need for outsourcing facilities to compound these drugs from bulk substances now that FDA-approved versions are available and shortages have resolved. The Commissioner framed the action as protecting patients and preserving the integrity of the drug-approval process.
Because the branded-drug shortages were already declared resolved, removing these substances from the 503B bulks list would eliminate the main remaining pathway for large-scale compounding; only narrow, patient-specific 503A compounding would remain in limited circumstances. The FDA invited public comments before a final determination, with a comment window running into late June 2026.
For consumers, this proposal signals that broadly available compounded GLP-1s are heading toward the exit. Compounded versions are not FDA-approved and have been associated with quality and dosing concerns; as approved products become more accessible and, in some channels, lower-priced, the historical case for compounded versions weakens further. The practical guidance is unchanged but sharper: prioritize FDA-approved GLP-1s obtained through licensed prescribers and pharmacies.
Watch the outcome of the comment period and whether the FDA finalizes the exclusion, which analysts expect could substantially reduce compounded supply. Pricing and access for approved products will shape how patients are affected. For individuals currently using compounded GLP-1s, the prudent step is to discuss FDA-approved alternatives with a prescriber rather than turning to unregulated or online sources as legitimate compounded supply narrows.